Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Receives Average Recommendation of “Moderate Buy” from Brokerages

Posted by Brian Himes on Sep 30th, 2026

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) have received an average recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eleven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $56.25.

A number of equities analysts have commented on FTH shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday, September 14th. TD Cowen initiated coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, September 9th. They set a “buy” rating on the stock. BTIG Research reaffirmed a “buy” rating and issued a $55.00 price target on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. Robert W. Baird assumed coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They set an “outperform” rating and a $57.00 price target on the stock. Finally, Wall Street Zen downgraded Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday.

Get Our Latest Stock Analysis on Sensei Biotherapeutics

Institutional Investors Weigh In On Sensei Biotherapeutics

Institutional investors have recently made changes to their positions in the company. Bank of America Corp DE boosted its holdings in Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares during the period. Alyeska Investment Group L.P. bought a new position in Sensei Biotherapeutics during the 2nd quarter worth about $3,610,000. Renaissance Technologies LLC boosted its stake in shares of Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares in the last quarter. Stempoint Capital LP purchased a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at $4,188,000. Finally, Vivo Capital LLC purchased a new position in Sensei Biotherapeutics in the first quarter valued at about $22,758,000. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Stock Up 1.1%

NASDAQ FTH opened at $28.07 on Friday. The firm’s 50 day moving average price is $32.05. Sensei Biotherapeutics has a one year low of $7.45 and a one year high of $42.14. The company has a market cap of $725.33 million, a P/E ratio of -0.20 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping the consensus estimate of ($5.04) by $2.20. On average, equities analysts expect that Sensei Biotherapeutics will post -13.69 EPS for the current fiscal year.

About Sensei Biotherapeutics

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.